Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 5:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 1,119 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Dyslipidemia Clear all
Completed Phase 2 Interventional

Dose-Ranging Study Evaluating AVE1625 in Abdominally Obese Patients With Atherogenic Dyslipidemia

NCT00345410
View directory record Official record
Conditions
Obesity, Dyslipidemia
Interventions
AVE1625 B
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 19, 2008 · Synced Oct 20, 2026, 5:31 PM EDT
Completed Phase 3 Interventional Results available

Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed Dyslipidemia

NCT01854918
View directory record Official record
Conditions
Hyperlipidemia and Mixed Dyslipidemia
Interventions
Evolocumab, Standard of Care
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 85 Years
Enrollment
3,681 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
107
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 94 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Oct 20, 2026, 5:31 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Bioavailability of EPA and DHA From Two Dietary Supplements

NCT01908374
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
DHA-rich fish oil versus Phospholipid-rich fish oil
Dietary Supplement
Lead sponsor
Arctic Nutrition AS
Industry
Eligibility
18 Years to 59 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Addison, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 25, 2013 · Synced Oct 20, 2026, 5:31 PM EDT
Completed Phase 2 Interventional Results available

Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Partial Lipodystrophy (FPL)

NCT03514420
View directory record Official record
Conditions
Familial Partial Lipodystrophy
Interventions
AKCEA-ANGPTL3-LRx
Drug
Lead sponsor
Akcea Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 16, 2021 · Synced Oct 20, 2026, 5:31 PM EDT
Completed Phase 2 Interventional Results available

Safety of Red Yeast Rice for High Cholesterol in Individuals With Statin Intolerance

NCT00639223
View directory record Official record
Conditions
Hypercholesterolemia, Statin-Associated Myopathy
Interventions
Red Yeast Rice, Pravastatin, Lifestyle modification program
Dietary Supplement · Drug · Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years to 80 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 18, 2010 · Synced Oct 20, 2026, 5:31 PM EDT
Completed No phase listed Observational

Prenatal Screening For Smith-Lemli-Opitz Syndrome

NCT00070850
View directory record Official record
Conditions
Smith-Lemli-Opitz Syndrome, Pregnancy
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Female only
Enrollment
1,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Scarborough, Maine
Source: ClinicalTrials.gov public record
Updated Jul 2, 2007 · Synced Oct 20, 2026, 5:31 PM EDT
Completed Phase 2 Interventional Results available

A Study of AZD8233 in Participants With Dyslipidemia

NCT04641299
View directory record Official record
Conditions
Dyslipidaemia
Interventions
AZD8233, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
10
States / cities
Roseville, California • Inverness, Florida • Jacksonville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2022 · Synced Oct 20, 2026, 5:31 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Diets Enriched With Pecans

NCT04376632
View directory record Official record
Conditions
Hypercholesterolemia, Obesity
Interventions
Pecan ADD, Pecan SUB
Dietary Supplement
Lead sponsor
University of Georgia
Other
Eligibility
30 Years to 75 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Athens, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 1, 2022 · Synced Oct 20, 2026, 5:31 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia

NCT07477704
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Alirocumab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
34
States / cities
Anniston, Alabama • Cullman, Alabama • Anaheim, California + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 20, 2026, 5:31 PM EDT
Completed Phase 3 Interventional

The Health Outcomes Management and Evaluation (HOME) Study

NCT01228032
View directory record Official record
Conditions
Diabetes, Hyperlipidemia, Heart Disease, High Blood Pressure
Interventions
Care team
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Marietta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 26, 2016 · Synced Oct 20, 2026, 5:31 PM EDT
Completed Phase 2 Interventional Results available

Study of Evinacumab (REGN1500) in Participants With Persistent Hypercholesterolemia

NCT03175367
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Evinacumab, Matching placebo, Background Lipid Modifying Therapy (LMT)
Drug · Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
23
States / cities
Los Angeles, California • Newport Beach, California • Boca Raton, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2023 · Synced Oct 20, 2026, 5:31 PM EDT
Completed Phase 3 Interventional

Efficacy Study of Pioglitazone and Glimepiride on the Rate of Progression of Atherosclerotic Disease.

NCT00225264
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Pioglitazone, Glimepiride
Drug
Lead sponsor
Takeda
Industry
Eligibility
45 Years to 85 Years
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 28, 2012 · Synced Oct 20, 2026, 5:31 PM EDT
Withdrawn Phase 2 Interventional

Study of MB07811 in Subjects With Hypercholesterolemia

NCT00879112
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
MB07811, Placebo
Drug
Lead sponsor
Ligand Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
11
States / cities
San Diego, California • Jacksonville, Florida • Pembroke Pines, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2011 · Synced Oct 20, 2026, 5:31 PM EDT
Active, not recruiting Phase 3 Interventional

Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy

NCT02262832
View directory record Official record
Conditions
Lipodystrophy, Diabetes, Hyperlipidemia
Interventions
Metreleptin
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
6 Months to 98 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 20, 2026, 5:31 PM EDT
Completed Phase 3 Interventional Results available

Trial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects With High CV Risk and Elevated LDL-C

NCT03814187
View directory record Official record
Conditions
ASCVD, Elevated Cholesterol, Heterozygous Familial Hypercholesterolemia, Homozygous Familial Hypercholesterolemia
Interventions
Inclisiran Sodium
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
3,275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
141
States / cities
Birmingham, Alabama • Foley, Alabama • Huntsville, Alabama + 109 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Oct 20, 2026, 5:31 PM EDT
Completed Phase 3 Interventional

Efficacy of Lapaquistat Acetate Alone or Combined With Simvastatin in Subjects With Hypercholesterolemia

NCT00286481
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Lapaquistat acetate and simvastatin, Simvastatin
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
1,362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
50
States / cities
Huntsville, Alabama • Chandler, Arizona • Scottsdale, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated May 24, 2012 · Synced Oct 20, 2026, 5:31 PM EDT
Recruiting Not applicable Interventional

Comparing Direct vs Indirect Methods for Cascade Screening

NCT05348564
View directory record Official record
Conditions
Long QT Syndrome, Familial Hypercholesterolemia, Ethics, Genetic Testing
Interventions
Direct contact of family members for cascade screening of relevant variants
Behavioral
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Lancaster, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 20, 2026, 5:31 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Fish Oil on Plasma Triglycerides in Adults

NCT00804427
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
Fish oil (90% triglycerides), Fish oil (60% triglycerides), Fish oil (ethyl esters), Soy oil
Dietary Supplement
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 22, 2023 · Synced Oct 20, 2026, 5:31 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Ezetimibe on the Absorption of Oxidized Cholesterol

NCT00794677
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
ezetimibe, placebo
Drug
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
18 Years to 70 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Oct 20, 2026, 5:31 PM EDT
Recruiting No phase listed Observational

Bempedoic Acid Pregnancy Surveillance Program

NCT05103254
View directory record Official record
Conditions
Pregnancy, Hyperlipidemias
Interventions
Bempedoic Acid, Bempedoic Acid / Ezetimibe
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Timeline
2021 – 2032
U.S. locations
1
States / cities
Morrisville, North Carolina
Source: ClinicalTrials.gov public record
Updated May 17, 2024 · Synced Oct 20, 2026, 5:31 PM EDT
Terminated Phase 2 Interventional Results available

Drug Therapy Induced Weight Loss to Improve Blood Vessel Function in Subjects With Obesity

NCT01351753
View directory record Official record
Conditions
Obesity, Metabolic Syndrome X
Interventions
Metformin, Orlistat, Topiramate, Placebo
Drug
Lead sponsor
University of Iowa
Other
Eligibility
40 Years to 75 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 20, 2026, 5:31 PM EDT
Completed Phase 3 Interventional Results available

Changes in Lipids and Safety of Raltegravir in HIV+ Patients With Hyperlipidemia While on Current Standard Therapy

NCT00887653
View directory record Official record
Conditions
HIV, Hyperlipidemia, Hypertriglyceridemia, HIV Infections
Interventions
raltegravir
Drug
Lead sponsor
The Miriam Hospital
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 10, 2014 · Synced Oct 20, 2026, 5:31 PM EDT
Completed Phase 2 Interventional Results available

Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients

NCT01811472
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease (NAFLD)
Interventions
LCQ908, placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 74 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
11
States / cities
Mobile, Alabama • San Diego, California • Gainesville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2016 · Synced Oct 20, 2026, 5:31 PM EDT
Completed Phase 4 Interventional

Study to Compare Welchol and TriCor to TriCor Alone in Patients With High Cholesterol

NCT00754039
View directory record Official record
Conditions
Hypercholesterolemia, Hyperlipidemia, Familial Combined
Interventions
colesevelam HCl tablets and fenofibrate tablets, fenofibrate tablets and Welchol placebo tablets
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
30 Years to 70 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
10
States / cities
Longwood, Florida • Ocala, Florida • Winterpark, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2015 · Synced Oct 20, 2026, 5:31 PM EDT